0
Original Research: PULMONARY HYPERTENSION |

Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension*: Potential Implications for the Design of Future Clinical Trials

Donald L. Helman, Jr, MD, FCCP; Alexander W. Brown, MD; Jeffrey L. Jackson, MD, MPH; Andrew F. Shorr, MD, MPH, FCCP
Author and Funding Information

*From the Dwight David Eisenhower Army Medical Center (Drs. Helman and Brown), Ft. Gordon, GA; The Uniformed Services University of the Health Sciences (Dr. Jackson), Bethesda, MD; and Washington Hospital Center (Dr. Shorr), Washington, DC.

Correspondence to: Donald L. Helman, Jr, MD, FCCP, Dwight David Eisenhower Army Medical Center, 300 Hospital Rd, ATTN: Pulmonary Disease Clinic, Ft. Gordon, GA 30905; e-mail: donald.helman@gmail.com



Chest. 2007;132(3):764-772. doi:10.1378/chest.07-0236
Text Size: A A A
Published online

Background: Placebo is commonly used in short-term randomized trials for pulmonary arterial hypertension (PAH). Currently, outcome data regarding placebo are lacking. We conducted a systematic review and performed a metaanalysis to assess its effect.

Methods: Articles were identified via a query of MEDLINE and EMBASE using the following terms: “pulmonary hypertension”; “clinical trial”; “six minute walk”; “pulmonary hemodynamic”; and “survival.” A manual bibliography search of selected trials, reviews, and guidelines was performed. The inclusion criteria were as follows: randomized, placebo-controlled with data reported at baseline and at 12 to 18 weeks. Two reviewers independently abstracted: 6-min walk distance, pulmonary hemodynamic measures and frequency of death, clinical worsening, and change in New York Heart Association/World Health Organization functional class. The data were pooled using a random-effects model.

Results: Thirteen of the 688 articles identified met the inclusion criteria (a total of 868 placebo-treated patients). After 12 to 18 weeks, the 6-min walk distance decreased by 8.4 m (95% confidence interval [CI], −14.6 to −2.2) and pulmonary vascular resistance increased by 58.9 dyne . s . cm−5 (95% CI, 27.6 to 90.1). Placebo-treated patients were 1.81 times more likely to experience a clinical worsening (95% CI, 1.30 to 2.53). Placebo treatment was not associated with a difference in mortality.

Conclusions: Patients with PAH who receive placebo are more likely to experience clinical deteriorations. Further debate is needed regarding the design of future clinical trials. Research efforts should focus on evaluating existing medications against one another and comparing novel therapies with currently accepted ones.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543